Press "Enter" to skip to content

CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab – Nasdaq

admin 0

CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab  Nasdaq

VANCOUVER, Washington, Sept. 04, 2019– CytoDyn Inc.,, a late stage biotechnology company developing leronlimab, a CCR5 antagonist with the.

“liver cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *